½ÃÀ庸°í¼­
»óǰÄÚµå
1493343

¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Á¦Ç°º°, ¿ëµµº°, ½Ã¼úº°, ±â¼úº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

U.S. Apheresis Equipment Market Size, Share & Trends Analysis Report By Product (Disposable Apheresis Kits, Device), By Application (Renal Disease, Neurology), By Procedure, By Technology, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 80 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå ±Ô¸ð´Â 2024-2030³â CAGR 8.6%·Î È®´ëÇϸç, 2030³â¿¡´Â 16¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¾ÆÆä·¹½Ã½º ±â¼úÀÇ Áö¼ÓÀûÀÎ °³¼±À¸·Î º¸´Ù È¿À²ÀûÀÌ°í »ç¿ëÇÏ±â Æí¸®ÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ Àåºñ°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ½ÅºÎÀü, ¾Ï, ÀÚ°¡¸é¿ªÁúȯ µî ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϸ鼭 ¾ÆÆä·¹½Ã½º ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ±¹¸³ÀÇÇеµ¼­°ü¿¡ µû¸£¸é 2023³â ¹Ì±¹¿¡¼­ ¾à 1,958,310°ÇÀÇ »õ·Î¿î ¾Ï »ç·Ê°¡ °üÂûµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ¾ÆÆä·¹½Ã½º Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ½ÃÀå¿¡¼­ÀÇ ½ÅÁ¦Ç° Ãâ½Ã´Â Àåºñ¿¡ Çõ½ÅÀûÀÎ ±â´É°ú ±â¼ú Áøº¸¸¦ °¡Á®¿Í È¿À²¼º, Á¤È®¼º ¹× ¼º´ÉÀ» Çâ»ó½Ãŵ´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ¾ÆÆä·¹½Ã½º Àåºñ°¡ ¾ÈÀü ¹× À¯È¿¼º ±âÁØÀ» ÃæÁ·ÇÏ´Â °ÍÀ» º¸ÀåÇϸç, ÀÌ´Â º´¿ø ¹× Ŭ¸®´Ð°ú °°Àº ÃÖÁ¾»ç¿ëÀÚ¿¡°Ô ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î Ç÷¾× ¹× ¹ÙÀÌ¿À Ä¡·á ÁøÈï Çùȸ¿¡ µû¸£¸é 2023³â 8¿ù Å׸£¸ð BCT´Â ·¹ºñ¿ì½º ÀÚµ¿ ÀüÇ÷ ó¸® ½Ã½ºÅÛ¿¡ ´ëÇÑ FDA ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. ÀÌ´Â ¼ÒºñÀÚÀÇ ½Å·Ú¸¦ ³ôÀÌ°í ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀÔ´Ï´Ù.

¹Ì±¹ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î´Â ÀÏȸ¿ë ¾ÆÆä·¹½Ã½º ŰƮ°¡ 2023³â 70% ÀÌ»óÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ´Â °¢ ŰƮ´Â ÇÑ ¹ø¸¸ »ç¿ëÇÏ°í Æó±âÇϱ⠶§¹®¿¡ ȯÀÚ °£ ±³Â÷ ¿À¿° ¹× °¨¿° ÀüÆÄÀÇ À§ÇèÀ» Á¦°ÅÇÒ ¼ö Àִٴ Ư¡¿¡ ±âÀÎÇÕ´Ï´Ù.
  • µð¹ÙÀ̽º ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¿ëµµº°·Î´Â ½Å°æ ºÐ¾ß°¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¾ÆÆä·¹½Ã½º´Â Áúº´À» À¯¹ßÇÏ´Â Ç×ü¿Í ¸é¿ª¼¼Æ÷¸¦ Á¦°ÅÇÏ¿© ¿°ÁõÀ» ¾ïÁ¦ÇÏ°í ½Å°æÀ» º¸È£ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
  • ¹Ì±¹ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ½ÃÀå ±â¾÷À¸·Î´Â Haemonetics Corporation, Fresenius Kabi, B. Braun SE, Mallinckrodt Pharmaceuticals µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¦Ç° ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ì±¹ÀÇ ¼ººÐ ºÐ¼®±â ½ÃÀå : Á¦Ç°º° Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ÀÏȸ¿ë ¾ÆÆä·¹½Ã½º ŰƮ
  • µð¹ÙÀ̽º

Á¦5Àå ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ì±¹ÀÇ ¼ººÐ ºÐ¼®±â ½ÃÀå, ¿ëµµº° Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ½ÅÀ庴
  • ½Å°æ
  • Ç÷¾×
  • ±âŸ

Á¦6Àå ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå : ½Ã¼ú ÃßÁ¤¡¤µ¿Ç⠺м®

  • ÀýÂ÷ÀÇ ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå : ÀýÂ÷º° Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • Photopheresis
  • Plasmapheresis
  • LDL ¾ÆÆä·¹½Ã½º
  • ¹éÇ÷±¸ ¾ÆÆä·¹½Ã½º
  • ÀûÇ÷±¸ ¾ÆÆä·¹½Ã½º

Á¦7Àå ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®

  • Å×Å©³î·¯Áö ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ±â¼ú Àü¸Á¿¡ ÀÇÇÑ ¹Ì±¹ÀÇ ¼ººÐ ºÐ¼®±â ½ÃÀå
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ¸·¿©°ú
  • ¿ø½ÉºÐ¸®

Á¦8Àå ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • Áö¿ªº° ¹Ì±¹ÀÇ ¾ÆÆä·¹½Ã½º Àåºñ ½ÃÀå Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®
  • ¼­ºÎ
  • Áß¼­ºÎ
  • ºÏµ¿ºÎ
  • ³²¼­ºÎ
  • ³²µ¿ºÎ

Á¦9Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷/°æÀï ºÐ·ù
  • º¥´õ ±¸µµ
  • ±â¾÷ °³¿ä
    • Haemonetics Corporation
    • Fresenius Kabi
    • B. Braun SE
    • Mallinckrodt Pharmaceuticals
    • Nikkiso Co., Ltd.
    • Asahi Kasei Medical Co., Ltd.
    • Terumo BCT
KSA 24.06.20

U.S. Apheresis Equipment Market Growth & Trends:

The U.S. apheresis equipment market size is anticipated to reach USD 1.64 billion by 2030, expanding at a CAGR of 8.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Continuous improvements in apheresis technology have led to the development of more efficient, user-friendly, and cost-effective equipment. The rise in the prevalence of chronic diseases in the U.S., such as kidney failure, cancer, and autoimmune disorders, has led to a higher demand for apheresis procedures. For instance, according to the National Library of Medicine, in 2023, approximately 1,958,310 new cancer cases were observed in the U.S., that in turn, drives the need for apheresis equipment.

New product launches in the U.S. market bring innovative features and technological advancements to the equipment, improving their efficiency, accuracy, and performance. Regulatory approvals ensure that the apheresis equipment meets safety and efficacy standards, which is crucial for the end-users, such as hospitals and clinics. For instance, according to the Association for the Advancement of Blood & Biotherapies, in August 2023, Terumo BCT received its FDA clearance for its Reveous Automated Whole Blood Processing System. This boosts consumer confidence and contributes to the growth of the market.

U.S. Apheresis Equipment Market Report Highlights:

  • Based on product, disposable apheresis kits dominated the market with more than 70% share in 2023 owing to the feature of eliminating the risk of cross-contamination and infection transmission between patients, as each kit is used only once and then discarded
  • The device segment is expected to grow at the fastest CAGR over the forecast period
  • Based on application, the neurology segment held the largest market share in 2023. Apheresis helps to remove the disease-causing antibodies or immune cells, thus reducing inflammation and protecting the nerves
  • Market players operating in the U.S. apheresis equipment market include Haemonetics Corporation, Fresenius Kabi, B. Braun SE, Mallinckrodt Pharmaceuticals

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Procedure
    • 1.2.4. Technology
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Application
    • 2.2.3. Procedure
    • 2.2.4. Technology
  • 2.3. Competitive Insights

Chapter 3. U.S. Apheresis Equipment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Apheresis Equipment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Apheresis Equipment Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Apheresis Equipment Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Disposable Apheresis Kits
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Device
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Apheresis Equipment Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Apheresis Equipment Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Renal Disease
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Neurology
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hematology
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Apheresis Equipment Market: Procedure Estimates & Trend Analysis

  • 6.1. Procedure Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Apheresis Equipment Market by Procedure Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Photopheresis
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Plasmapheresis
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. LDL Apheresis
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Plateletpheresis
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Leukapheresis
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Erythrocytapheresis
      • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Others
      • 6.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Apheresis Equipment Market: Technology Estimates & Trend Analysis

  • 7.1. Technology Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Apheresis Equipment Market by Technology Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.4.1. Membrane Filtration
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Centrifugation
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Apheresis Equipment Market: Region Estimates & Trend Analysis

  • 8.1. Regional Market Share, 2023 & 2030
  • 8.2. U.S. Apheresis Equipment Market by Region Outlook
  • 8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 8.3.1. West
      • 8.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 8.3.2. Midwest
      • 8.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Northeast
      • 8.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.4. Southwest
      • 8.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.5. Southeast
      • 8.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company heat map analysis, 2023
  • 9.4. Company Profiles
    • 9.4.1. Haemonetics Corporation
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Fresenius Kabi
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. B. Braun SE
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Mallinckrodt Pharmaceuticals
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Nikkiso Co., Ltd.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Asahi Kasei Medical Co., Ltd.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Terumo BCT
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦